NCT02789878View on ClinicalTrials.gov

Neoadjuvant Androgen Deprivation Therapy Plus Abiraterone With or Without Apalutamide for High-Risk Prostate Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 24, 2019

Primary Completion Date

April 30, 2022

Study Completion Date

August 1, 2022

Conditions

Prostate Cancer

Interventions

DRUG

Goserelin

Androgen Deprivation Therapy

DRUG

Prednisone

Corticosteroid

DRUG

Abiraterone

CYP17 inhibitor

DRUG

Apalutamide

Androgen-receptor antagonist

Trial Locations (1)

01246-0000

Instituto do Cancer do Estado de Sao Paulo, São Paulo

All Listed Sponsors

collaborator

Janssen, LP

INDUSTRY

lead

Instituto do Cancer do Estado de São Paulo

OTHER

NCT02789878 - Neoadjuvant Androgen Deprivation Therapy Plus Abiraterone With or Without Apalutamide for High-Risk Prostate Cancer | Biotech Hunter | Biotech Hunter